Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
September 02 2021 - 8:00AM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on
developing FT218, an investigational, once-nightly formulation of
sodium oxybate for treating excessive daytime sleepiness and
cataplexy in adults with narcolepsy, announced today that Greg
Divis, Chief Executive Officer of Avadel, will participate in the
following upcoming virtual investor conferences in September:
- 2021 Wells Fargo Virtual Healthcare
Conference: Fireside chat on Friday, September 10, 2021 at 4:00
p.m. E.T.
- Morgan Stanley 19th Annual Global
Healthcare Conference: Fireside chat on Thursday, September 9, 2021
at 9:30 a.m. E.T.
- H.C. Wainwright’s 23rd Annual
Global Investment Conference: Fireside chat on Monday, September
13, 2021 at 7:00 a.m. E.T.
- Oppenheimer Fall Healthcare Life
Sciences & MedTech Summit: Fireside chat on Wednesday,
September 22, 2021 at 10:45 a.m. E.T.
A live webcast of these events, as well as archived recordings,
will be available on Avadel’s Investor Relations website,
investors.avadel.com, for 90 days following each conference.
About Avadel Pharmaceuticals plcAvadel
Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company
primarily focused on the development and FDA approval of FT218, an
investigational, once-nightly, extended-release formulation of
sodium oxybate designed to treat excessive daytime sleepiness and
cataplexy in adults with narcolepsy. For more information, please
visit www.avadel.com.
Investor Contact:Courtney TurianoStern Investor
Relations, Inc. Courtney.Turiano@sternir.com (212) 698-8687
Media Contact:Nicole Raisch GoelzReal
Chemistryngoelz@realchemistry.com(408) 568-4292
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Sep 2023 to Sep 2024